Illumina is trading at $213.14 (-18.82%) amid a technology-led selloff, with no confirmed company-specific catalyst.

  • No company-specific announcement dated October 16 explains the drop; Illumina’s latest listed release was its October 14 BioInsight launch.
  • Reuters reported technology and communication services drove market losses on October 16 amid concerns about AI infrastructure debt and higher borrowing costs.
  • This points to broad risk-off sentiment, but the exact cause of the unusually sharp after-hours move remains unverified.